UNSPSC 51373201: Dioxaphetyl

This classification denotes an opioid receptor agonist and opioid and analgesic agent with the molecular formula C22H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G751H98FY4, chemically known as 4-morpholinebutyric acid, alpha,alpha-diphenyl-, ethyl ester but generally known as dioxaphetyl butyrate, which bears US NIH Compound Identifier 48194. European Medicines Agency schedules Dioxaphetyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07202MIG.

The term DIOXAPHETYL is an International Non-Proprietary Name. SMILES: CCOC(=O)C(CCN1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3.

UNSPSC 51373201 Dioxaphetyl is a Commodity code that maps nominally to pharmaceutical chemical compounds, but the recent state and local solicitation activity shows a sharp mismatch: Seminole County, Florida's IFB60459723LAS sought 1,900 units of naloxone and 800 safe drug deactivation systems annually, neither of which are dioxaphetyl products. The code appears to see minimal or misclassified recent activity in state and local procurement; the single available opportunity reflects a public-health-focused purchase of opioid-reversal and drug-disposal equipment rather than the chemical compound the code nominally covers.

Seminole County's procurement, posted June 30, 2026 with an IFB response deadline of July 26, 2023, required quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with all shipping costs included in vendor proposals. Bidders had to meet standard compliance requirements including E-Verify authorization, drug-free workplace certification, and proof of workers' compensation and general liability insurance. The contract was structured as a fixed-fee award with an initial two-year term and one-year renewal option, subject to a three-month probationary termination clause and potential FEMA-related federal compliance obligations including Clean Air Act and Water Pollution Control Act adherence. No set-aside designations for disadvantaged enterprises were specified. The code does not currently show sufficient recent activity under its intended pharmaceutical-chemical scope to support a reliable market characterization for business development purposes.